{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T03:50:36Z","timestamp":1768535436083,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus L\u00fcbeck"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Klin Intensivmed Notfmed"],"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund und Fragestellung<\/jats:title>\n                    <jats:p>Inwieweit Verlegungen kritisch kranker, SARS-CoV-2-positiver Patienten an ein terti\u00e4res Zentrum Einfluss auf die Mortalit\u00e4t haben bzw. wie pr\u00e4zise eine Mortalit\u00e4tspr\u00e4diktion mittels SAPS-II-Score ist, wurde bisher in Deutschland nur unzureichend untersucht.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methode<\/jats:title>\n                    <jats:p>Es erfolgte eine retrospektive Analyse der intensivmedizinisch versorgten SARS-CoV-2-Patienten, die zwischen 01.\u00a0M\u00e4rz 2020 und 31.\u00a0Dezember 2021 an einem terti\u00e4ren Zentrum behandelt und entweder direkt dort (PV) aufgenommen oder im Krankheitsverlauf sekund\u00e4r zuverlegt wurden (SV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>\n                      165 SARS-CoV-2-Patienten mit SAPS-II-Score wurden intensivmedizinisch versorgt. Die SV-Patienten waren signifikant j\u00fcnger (SV: 62,2 Jahre [IQR: 51,9\u201372,4] vs. PV: 70,8 Jahre [IQR: 58,3\u201379,9],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f\n                      <jats:italic>=<\/jats:italic>\n                      \u2009\n                      <jats:italic>0,002<\/jats:italic>\n                      ) und wurden l\u00e4nger beatmet (SV 16,5 Tage [IQR: 7\u201331] vs. PV 7\u00a0Tage [IQR: 4\u201311],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f\n                      <jats:italic>&lt;<\/jats:italic>\n                      \u2009\n                      <jats:italic>0,001<\/jats:italic>\n                      ) bei jedoch gleicher Krankenhausmortalit\u00e4t (SV 53,3\u202f% vs. PV 45,7\u202f%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f\n                      <jats:italic>=<\/jats:italic>\n                      \u2009\n                      <jats:italic>0,41<\/jats:italic>\n                      ). Der SAPS-II-Score untersch\u00e4tzte die prognostizierte Sterblichkeit in beiden Kollektiven (SV 15,2\u202f% [IQR: 7,9\u201326,6] vs. PV 19,6\u202f% [IQR: 9,2\u201334,7],\n                      <jats:italic>p<\/jats:italic>\n                      \u202f\n                      <jats:italic>=<\/jats:italic>\n                      \u2009\n                      <jats:italic>0,17<\/jats:italic>\n                      ), ohne dass Unterschiede im \u00dcberleben zwischen beiden Kollektiven erkennbar waren.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diskussion<\/jats:title>\n                    <jats:p>Die prognostische Aussagekraft des SAPS-II-Scores ist f\u00fcr SARS-CoV-2-Patienten limitiert. Eine Verlegung der intensivmedizinisch zu behandelnden Patienten erscheint sinnvoll, da die Mortalit\u00e4t unabh\u00e4ngig davon, ob Patienten prim\u00e4r im terti\u00e4ren Zentrum aufgenommen oder im Verlauf verlegt werden, vergleichbar ist.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00063-025-01394-2","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T11:28:23Z","timestamp":1768303703000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Erfahrungen aus der SARS-CoV-2-Pandemie am UKSH in L\u00fcbeck","Experiences from SARS-CoV-2 pandemic at UKSH L\u00fcbeck"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9895-590X","authenticated-orcid":false,"given":"Matthias","family":"Mezger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Wolfrum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toni","family":"P\u00e4tz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolin","family":"Schmoll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"Eitel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Graf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"24","key":"1394_CR1","doi-asserted-by":"publisher","first-page":"2957","DOI":"10.1001\/jama.1993.03510240069035","volume":"270","author":"JR Le Gall","year":"1993","unstructured":"Le Gall\u00a0JR, Lemeshow\u00a0S, Saulnier\u00a0F (1993) A\u00a0new Simplified Acute Physiology Score (SAPS II) based on a\u00a0European\/North American multicenter study. JAMA 270(24):2957\u20132963","journal-title":"JAMA"},{"issue":"5","key":"1394_CR2","doi-asserted-by":"publisher","first-page":"e0196197","DOI":"10.1371\/journal.pone.0196197","volume":"13","author":"JY Choi","year":"2018","unstructured":"Choi\u00a0JY et\u00a0al (2018) Performance on the APACHE II, SAPS II, SOFA and the OHCA score of post-cardiac arrest patients treated with therapeutic hypothermia. PLoS ONE 13(5):e196197","journal-title":"PLoS ONE"},{"issue":"4","key":"1394_CR3","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jcrc.2007.06.002","volume":"22","author":"AD Hill","year":"2007","unstructured":"Hill\u00a0AD et\u00a0al (2007) Interhospital transfer of critically ill patients: Demographic and outcomes comparison with nontransferred intensive care unit patients. J\u00a0Crit Care 22(4):290\u2013295","journal-title":"J Crit Care"},{"issue":"1","key":"1394_CR4","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13613-021-00841-5","volume":"11","author":"B Painvin","year":"2021","unstructured":"Painvin\u00a0B et\u00a0al (2021) Inter-hospital transport of critically ill patients to manage the intensive care unit surge during the COVID-19 pandemic in France. Ann Intensive Care 11(1):54","journal-title":"Ann Intensive Care"},{"issue":"1","key":"1394_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/s13613-021-00933-2","volume":"11","author":"M-A Sanchez","year":"2021","unstructured":"Sanchez\u00a0M\u2011A et\u00a0al (2021) Impact of ICU transfers on the mortality rate of patients with COVID-19: insights from comprehensive national database in France. Ann Intensive Care 11(1):151","journal-title":"Ann Intensive Care"},{"issue":"3","key":"1394_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/17511437221111638","volume":"24","author":"AJ Stark","year":"2023","unstructured":"Stark\u00a0AJ, Chohan\u00a0S (2023) The association of intensive care capacity transfers with survival in COVID-19\u00a0patients from a\u00a0Scottish district general hospital: A\u00a0retrospective cohort study. J\u00a0Intensive Care Soc 24(3):277\u2013282","journal-title":"J Intensive Care Soc"},{"issue":"1","key":"1394_CR7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/00003246-199601000-00012","volume":"24","author":"DR Miranda","year":"1996","unstructured":"Miranda\u00a0DR, de Rijk\u00a0A, Schaufeli\u00a0W (1996) Simplified therapeutic intervention scoring system: the TISS-28\u00a0items\u2014results from a\u00a0multicenter study. Crit Care Med 24(1):64\u201373","journal-title":"Crit Care Med"},{"issue":"12","key":"1394_CR8","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/j.cmi.2020.08.011","volume":"26","author":"I Nachtigall","year":"2020","unstructured":"Nachtigall\u00a0I et\u00a0al (2020) Clinical course and factors associated with outcomes among 1904 patients hospitalized with COVID-19 in Germany: an observational study. Clin Microbiol Infect 26(12):1663\u20131669","journal-title":"Clin Microbiol Infect"},{"key":"1394_CR9","doi-asserted-by":"crossref","unstructured":"Brehm TT et\u00a0al (2021) Patient Characteristics and Clinical Course of COVID-19\u00a0Patients Treated at a\u00a0German Tertiary Center during the First and Second Waves in the Year 2020. J\u00a0Clin Med 10(11)","DOI":"10.3390\/jcm10112274"},{"issue":"5","key":"1394_CR10","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/S2213-2600(21)00101-6","volume":"9","author":"C Karagiannidis","year":"2021","unstructured":"Karagiannidis\u00a0C et\u00a0al (2021) Major differences in ICU admissions during the first and second COVID-19 wave in Germany. Lancet Respir Med 9(5):e47\u2013e48","journal-title":"Lancet Respir Med"},{"issue":"9","key":"1394_CR11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S2213-2600(20)30316-7","volume":"8","author":"C Karagiannidis","year":"2020","unstructured":"Karagiannidis\u00a0C et\u00a0al (2020) Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med 8(9):853\u2013862","journal-title":"Lancet Respir Med"},{"key":"1394_CR12","doi-asserted-by":"publisher","first-page":"100998","DOI":"10.1016\/j.ehb.2021.100998","volume":"42","author":"S Yakubenko","year":"2021","unstructured":"Yakubenko\u00a0S (2021) Home alone? Effect of weather-induced behaviour on spread of SARS-CoV\u20112 in Germany. Econ Hum Biol 42:100998","journal-title":"Econ Hum Biol"},{"issue":"1","key":"1394_CR13","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1186\/s12879-021-06585-8","volume":"21","author":"M Jin","year":"2021","unstructured":"Jin\u00a0M et\u00a0al (2021) Clinical characteristics and risk factors of fatal patients with COVID-19: a\u00a0retrospective cohort study in Wuhan, China. BMC Infect Dis 21(1):951","journal-title":"BMC Infect Dis"},{"issue":"4","key":"1394_CR14","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s11739-020-02543-5","volume":"16","author":"IJ N\u00fa\u00f1ez-Gil","year":"2021","unstructured":"N\u00fa\u00f1ez-Gil\u00a0IJ et\u00a0al (2021) Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19\u00a0registry. Intern Emerg Med 16(4):957\u2013966","journal-title":"Intern Emerg Med"},{"issue":"1","key":"1394_CR15","doi-asserted-by":"publisher","first-page":"e0262315","DOI":"10.1371\/journal.pone.0262315","volume":"17","author":"C Karagiannidis","year":"2022","unstructured":"Karagiannidis\u00a0C et\u00a0al (2022) Observational study of changes in utilization and outcomes in mechanical ventilation in COVID-19. PLoS ONE 17(1):e262315","journal-title":"PLoS ONE"},{"issue":"1","key":"1394_CR16","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/CCM.0000000000004674","volume":"49","author":"JR Stephens","year":"2021","unstructured":"Stephens\u00a0JR et\u00a0al (2021) Analysis of Critical Care Severity of Illness Scoring Systems in Patients With Coronavirus Disease 2019: A\u00a0Retrospective Analysis of Three U.K. ICUs. Crit Care Med 49(1):e105\u2013e107","journal-title":"Crit Care Med"},{"issue":"2","key":"1394_CR17","first-page":"e35423","volume":"15","author":"M Monk","year":"2023","unstructured":"Monk\u00a0M et\u00a0al (2023) A\u00a0Comparison of ICU Mortality Scoring Systems Applied to COVID-19. Cureus 15(2):e35423","journal-title":"Cureus"},{"issue":"1","key":"1394_CR18","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1186\/s12879-021-06866-2","volume":"21","author":"V Vicka","year":"2021","unstructured":"Vicka\u00a0V et\u00a0al (2021) Comparison of mortality risk evaluation tools efficacy in critically ill COVID-19\u00a0patients. BMC Infect Dis 21(1):1173","journal-title":"BMC Infect Dis"},{"key":"1394_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/membranes11030170","author":"A Supady","year":"2021","unstructured":"Supady\u00a0A et\u00a0al (2021) Outcome Prediction in Patients with Severe COVID-19 Requiring Extracorporeal Membrane Oxygenation\u2014A Retrospective International Multicenter Study. Membranes. https:\/\/doi.org\/10.3390\/membranes11030170","journal-title":"Membranes"},{"issue":"8","key":"1394_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s00134-021-06436-9","volume":"47","author":"PGH Metnitz","year":"2021","unstructured":"Metnitz\u00a0PGH et\u00a0al (2021) Evaluation and calibration of SAPS 3 in patients with COVID-19 admitted to intensive care units. Intensive Care Med 47(8):910\u2013912","journal-title":"Intensive Care Med"},{"issue":"1","key":"1394_CR21","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13054-021-03551-3","volume":"25","author":"C Jung","year":"2021","unstructured":"Jung\u00a0C et\u00a0al (2021) The impact of frailty on survival in elderly intensive care patients with COVID-19: the COVIP study. Crit Care 25(1):149","journal-title":"Crit Care"}],"container-title":["Medizinische Klinik - Intensivmedizin und Notfallmedizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-025-01394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00063-025-01394-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00063-025-01394-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:46:53Z","timestamp":1768474013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00063-025-01394-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":21,"alternative-id":["1394"],"URL":"https:\/\/doi.org\/10.1007\/s00063-025-01394-2","relation":{},"ISSN":["2193-6218","2193-6226"],"issn-type":[{"value":"2193-6218","type":"print"},{"value":"2193-6226","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"I.\u00a0Eitel hat Forschungsunterst\u00fctzung von Abbott erhalten, Beratungshonorare von Bayer und Novartis sowie Honorare f\u00fcr Vortr\u00e4ge von Bayer, Novartis, Abbott, Sanofi, Meril, Astra Zeneka, Corvia, BMS und Pfizer. M.\u00a0Mezger, S.\u00a0Wolfrum, T.\u00a0P\u00e4tz, K.\u00a0Schmoll und T.\u00a0Graf geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung; Ethik-Votum: UzL 21-159) durchgef\u00fchrt. Von allen beteiligten Patient\/-innen liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}